Abstract:Background: All patients with EGFR mutant lung cancers eventually develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI). In up to 30% of patients, the mechanism of acquired resistance remains unknown. MicroRNAs (miRNAs) represent a category of small non-coding RNAs commonly dysregulated in human malignancies and have been implicated in therapy resistance. The aim of this study was to understand the role of novel miRNAs in acquired EGFR TKI resistance in EGFR-mutant NSCLC. Method: The miR-483-3p expression in in vitro and in vivo models of acquired gefitinib resistance was examined by miRNA microarray and real-time RT-PCR. Transient or stable gain- and loss-of-function experiments were conducted in cell lines and nude mice, to evaluate the effects of miR-483-3p on sensitivity to gefitinib, proliferation, apoptosis, EMT and migration/invasion in vitro and in vivo. The molecular pathways affected by miR-483-3p were characterized using in silico target prediction, dual luciferase reporter assays and overexpression rescue experiments. The role of promoter methylation in miR-483-3p silencing was examined by real-time RT-PCR after demethylating agents treatment. Result: In this study, we reported the silencing of miR-483-3p and evidence for epithelial-to-mesenchymal transition (EMT) in both in vitro and in vivo EGFR-mutant lung cancer models with acquired resistance to gefitinib. In those tumor models, forced expression of miR-483-3p effectively increased sensitivity of gefitinib-resistant lung cancer cells to gefitinib by inhibiting proliferation, promoting apoptosis and reversing EMT phenotype. Mechanistically, miR-483-3p directly targeted integrin beta3, and thus repressed downstream FAK/Erk signaling pathway. In addition, miR-483-3p silencing in gefitinib-resistant NSCLC was due to hypermethylation of its own promoter. Conclusion: Our study provides a novel mechanism that epigenetic silencing of miR-483-3p promotes acquired EGFR TKI resistance in EGFR-mutant NSCLC by targeting integrin beta3. miR-483-3p may present a promising therapeutic target to overcome acquired resistance.The work was supported by National Natural Science Foundation of China (81372522 and 81773747), Science and Technology Commission of Shanghai Municipality (12ZR1416000 and 12140901400).

Data from Acquired Resistance to EGFR TKIs Mediated by TGFβ1/Integrin Β3 Signaling in EGFR-Mutant Lung Cancer

Acquired resistance to EGFR TKIs mediated by TGF-beta1/integrin beta3 signaling in EGFR-mutant lung cancer.

TGFβ1/integrin Β3 Positive Feedback Loop Contributes to Acquired EGFR TKI Resistance in EGFR-mutant Lung Cancer

Integrin Β1 Participates in Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer

Beta 1 Integrin Mediated Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Lung Cancer Cells

Integrin beta1 over-expression associates with resistance to tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.

Integrin Β1-Mediated Acquired Gefitinib Resistance in Non-Small Cell Lung Cancer Cells Occurs Via the Phosphoinositide 3-Kinase-dependent Pathway.

Integrin beta 1 enhances the epithelial-mesenchymal transition in association with gefitinib resistance of non-small cell lung cancer.

Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer

Supplementary Legends and Figure S1-S8 from Acquired Resistance to EGFR TKIs Mediated by TGFβ1/Integrin Β3 Signaling in EGFR-Mutant Lung Cancer

The Role of Up-Regulation of Integrin Β1 in Resistance to Gefitinib in Non-Small Cell Lung Cancer

Integrin beta 3 Promotes Resistance to EGFR-TKI in Non-Small-Cell Lung Cancer by Upregulating AXL through the YAP Pathway

EGFR-TKI Resistance in NSCLC Patients: Mechanisms and Strategies.

Integrin β3 Promotes Resistance to EGFR-TKI in Non-Small-Cell Lung Cancer by Upregulating AXL through the YAP Pathway

Β-Catenin Overexpression is Associated with Gefitinib Resistance in Non-Small Cell Lung Cancer Cells.

The Upregulation Of Osteopontin Mediates Acquired Resistance To Egfr-Tki In Nsclc Through Integrin/Fak Signaling

Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer

Reprogramming of TAMs via the STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung cancer

Abstract 415: Metabolic reprogramming driven by IGF2BP3-COX6B2 axis promotes acquired resistance to EGFR-TKIs in non-small lung cancer

Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance in EGFR-mutant NSCLC by targeting integrin beta3

TGF-β1 Induces Erlotinib Resistance in Non-Small Cell Lung Cancer by Down-Regulating PTEN